Drugs / r-Hirudin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05847205 | Nov 2022 → Dec 2023 | — | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | r-Hirudin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05847205 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Hirudin” NCT05847205 ↗ |
| Route | Subcutaneous | “beginning with 15 mg BID s.c starting 6 hours after surgery” NCT05847205 ↗ |